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Identification of fluorescent dyes that label the filamentous protein aggregates
characteristic of neurodegenerative disease, such as β-amyloid and tau in Alzheimer’s
disease, in a live cell culture system has previously been a major hurdle. Here we show
that pentameric formyl thiophene acetic acid (pFTAA) fulfills this function in living neurons
cultured from adult P301S tau transgenic mice. Injection of pFTAA into 5-month-old
P301S tau mice detected cortical and DRG neurons immunoreactive for AT100, an
antibody that identifies solely filamentous tau, or MC1, an antibody that identifies a
conformational change in tau that is commensurate with neurofibrillary tangle formation in
Alzheimer’s disease brains. In fixed cultures of dorsal root ganglion (DRG) neurons, pFTAA
binding, which also identified AT100 or MC1+ve neurons, followed a single, saturable
binding curve with a half saturation constant of 0.14µM, the first reported measurement
of a binding affinity of a beta-sheet reactive dye to primary neurons harboring filamentous
tau. Treatment with formic acid, which solubilizes filamentous tau, extracted pFTAA, and
prevented the re-binding of pFTAA and MC1 without perturbing expression of soluble
tau, detected using an anti-human tau (HT7) antibody. In live cultures, pFTAA only
identified DRG neurons that, after fixation, were AT100/MC1+ve, confirming that these
forms of tau pre-exist in live neurons. The utility of pFTAA to discriminate between living
neurons containing filamentous tau from other neurons is demonstrated by showing
that more pFTAA+ve neurons die than pFTAA-ve neurons over 25 days. Since pFTAA
identifies fibrillar tau and other misfolded proteins in living neurons in culture and in animal
models of several neurodegenerative diseases, as well as in human brains, it will have
considerable application in sorting out disease mechanisms and in identifying disease-
modifying drugs that will ultimately help establish the mechanisms of neurodegeneration
in human neurodegenerative diseases.
Keywords: hyperphosphorylated tau, neurofibrillary tangles, transgenic P301S tau mouse, dorsal root ganglion
neurons, Alzheimer’s disease, frontotemporal dementia (FTD), fluorescent vital fibrillar tau dye
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Introduction
Tau is a soluble microtubule-associated protein with dynamic
phospho-epitopes that is expressed throughout the CNS and PNS
(Cleveland et al., 1977; Binder et al., 1985). Its primary role is the
stabilization of microtubules thereby facilitating axonal transport
and maintaining proper neuronal morphology (Mandelkow and
Mandelkow, 2012). However, insoluble hyperphosphorylated
filamentous tau forms the neurofibrillary tangles (NFTs)
and Pick bodies that are diagnostic hallmarks of numerous
neurodegenerative diseases including Alzheimer’s disease (AD),
Pick’s disease, frontotemporal dementia with Parkinsonism
linked to chromosome 17, progressive supranuclear palsy and
cortical basal degeneration (Spillantini and Goedert, 2013).
Indeed, theMAPT (tau) gene haplotype H1/H1 is also associated
with memory dysfunction in patients with Parkinson’s disease
(Winder-Rhodes et al., 2015) and acts as an independent genetic
risk factor in pathologically proven PD (Charlesworth et al.,
2012). Moreover, abnormal NFTs of tau were also found in
the brains of Huntington’s disease patients (Fernandez-Nogales
et al., 2014; Vuono et al., 2015). The driving force behind
tau aggregation is not known but familial mutations in the
MAPT gene such as P301S can increase aggregation propensity
by reducing tau binding to microtubules, and possibly by
introducing a new phosphorylation site (Hong et al., 1998).
Individuals affected by this mutation have an early to midlife age
of onset and an aggressive disease progression (Bugiani et al.,
1999; Sperfeld et al., 1999; Yasuda et al., 2000; Lossos et al., 2003).
Although both beta-amyloid and tau form abnormal filaments
in AD, there is increasing evidence suggesting that tau is
necessary for mediating the ultimate neurodegeneration (Pooler
et al., 2013; Bloom, 2014). However, despite extensive research
into the mechanisms of degeneration, it is still unclear how tau
mediates its toxic effects neither in pure tauopathies, nor in the
context of beta amyloid plaques in AD. There is a continued
debate as to whether tau+ve NFTs induce cell death (Tomlinson
et al., 1970; Gomez-Isla et al., 1997; Mocanu et al., 2008;
Fatouros et al., 2012) or whether protein aggregates are benign
(Kuchibhotla et al., 2014) or even protective (Morsch et al., 1999;
Spires et al., 2006; Fox et al., 2011). Perhaps a “one hit” model,
which predicts that abnormally misfolded tau is both necessary
and sufficient for induction of toxicity, as was suggested to
account for the progression of several neurodegenerative diseases
(Clarke et al., 2000, modified by Clarke and Lumsden, 2005),
needs to be replaced by a “two hit” model, where another event,
which is not toxic per se, is required for tau to cause cell death.
The second hit could come from a myriad of sources, which
might also explain why it has been so difficult to demonstrate
a clear single mechanism of cell death in AD, unlike the more
defined cases of regulated cell death such as apoptosis during
development (Dekkers and Barde, 2013; Kole et al., 2013), which
fit a modified one hit model (Edwards and Tolkovsky, 1994), or
parthanatos (Fatokun et al., 2014).
To study whether cell autonomous mechanisms lead to tau
pathology and neurodegeneration, we turned to the transgenic
P301S tau mouse model, which develops progressive hallmarks
of tau pathology that culminate in neuronal cell death over 5
months. We showed previously that a subset of Dorsal Root
Ganglion (DRG) neurons from transgenic human P301S tau
mice develop progressive hallmarks of tau pathology in vivo and
in vitro with the same time course as that of CNS neurons (Allen
et al., 2002; Mellone et al., 2013). These neurons are unique in
that they can be cultured from adult mice for months, enabling
tau-dependent processes to be defined as tau evolves from a
soluble to a filamentous form with a characteristic acquisition
of different hyperphosphorylation and conformational patterns
(Mellone et al., 2013). Nevertheless, despite the presence of
sarkosyl-insoluble filamentous tau in DRG extracts and evidence
for conformational changes associated with filamentous tau in
cultured DRG neurons (Mellone et al., 2013), supported, for
example, by staining with the conformation-specific antibody
MC1 (Jicha et al., 1997, 1999), there has been no direct evidence
that tau adopts these conformations in living DRG neurons.
This is most likely due to the low intensity of specific signals
elicited by beta-sheet-reactive dyes such as thioflavins (Allen
et al., 2002) or FSB (Velasco et al., 2008) in the context of the
large volumes of the proprioceptive andmechanoceptive neurons
that express P301S tau in the transgenic model. The ability
to visualize filamentous tau aggregates in specific cells within
a heterogeneous culture would allow investigations of the cell
autonomous processes leading to toxicity or protection.
Recently a new family of luminescent conjugated
polythiophene dyes were described that detect various beta-
sheet containing proteins. Some members of this family are
capable of discriminating between different conformational
strains of PrPSc, the prion disease associated aggregate form
of normal prion protein PrPC, that would be indistinguishable
by immunohistochemistry alone (Sigurdson et al., 2007),
while others can detect beta amyloid and tau filaments in
post-mortem AD brains (Aslund et al., 2009). In particular, the
pentameric formyl thiophene acetic acid (pFTAA) is a highly
promising compound, as it can be used to distinguish different
conformations of beta-sheet containing proteins due to specific
conformation-dependent shifts in emission spectra depending
on the nature of the protein (Klingstedt et al., 2013). Intravenous
injection of pFTAA into APP23 mice was reported to produce
no discernable toxic effects on body weight, whole blood cell
counts, or histology of peripheral organs (Wegenast-Braun et al.,
2012). In AD brains, pFTAA co-labeled neurons immunostained
for AT8, an antibody that correlates with tau pathology (Aslund
et al., 2009), but given that AT8 is not specific to insoluble
filamentous tau aggregates, more complete characterization
with markers of filamentous tau was lacking. The clarity of
staining of neurons in a brain stem section from 6-month-old
P301S tau transgenic mice (Klingstedt et al., 2013), a stage at
which there is considerable accumulation of filamentous tau
in cortical and motor neurons in the CNS and spinal cord,
and the lack of apparent toxicity, prompted us to investigate
whether we could use pFTAA to identify living DRG neurons
that express filamentous tau. Here we show that pFTAA binds
filamentous tau aggregates in DRG neurons of P301S tau mice by
co-labeling with antibodies that detect aggregated/filamentous
tau. Moreover, we show that both live and fixed cultured DRG
neurons that are immunoreactive for these antibodies co-label
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with pFTAA. Importantly, we show that we can follow the
same fields of living pFTAA+ve neurons in long-term cultures
and quantify their death, an observation that will allow us to
underpin the mechanism of toxicity and identify drugs that may
alleviate it.
Materials and Methods
Animals
Homozygous mice transgenic for P301S tau (Allen et al., 2002),
or wild-type human 2N4R tau (Alz17) (Probst et al., 2000;
Clavaguera et al., 2009), and C57BL/6S (C57BL/6 OlaHsd;
Harlan) control mice were maintained as described previously
(Mellone et al., 2013). All procedures were performed in
accordance with the UK Home Office Regulations for the Care
and Use of Laboratory Animals and the UK Animals (Scientific
Procedures) Act 1986 and were approved by the Cambridge
University local ethical committee. To label neurons in vivo,
150 nmole of pFTAA in 150µl saline were injected intravenously
via the tail vein. After 48 h, the mouse was perfused transcardially
with PBS followed by 4% paraformaldehyde in PBS. Brains and
DRGs were removed and treated as described below.
Cultures
DRGneurons were cultured on 13mm coverslips or glass-bottom
dishes (MatTek) coated with poly-D-lysine and laminin and
maintained as described previously (Mellone et al., 2013). For
live labeling experiments, neurons were cultured for 7 days
in growth medium containing fluorodeoxyuridine (to remove
non-neuronal cells and neurons that die due to injury during
preparation), then washed and labeled in medium containing
3µM pFTAA and 0.1µg/ml propidium iodide (PI) for 30min
at room temperature. Medium containing PI was replaced every
3 days but no new pFTAA was added to ensure that no new
pathological tau assemblies forming over time as the culture
progressed were counted.
Immunocytochemistry
The brain and DRGs removed from P301S tau mice after
perfusion were incubated overnight in 4% PFA, washed and
stored in 30% sucrose in PBS (brain) or PBS containing 0.1%
sodium azide (DRG). Brain was cut into 30µm sections on
a sliding microtome (Leica SM2000 R). Prior to antibody
staining, brain sections or DRG were either immersed in acetone
for 10min (Nilsson et al., 2012), and then rehydrated in
water followed by PBS without detergent, or incubated in PBS
containing 0.3% triton X-100. There was no difference in the
staining intensity or pattern between the two procedures. To label
whole DRG ex vivo, DRG were isolated from 5-month-old P301S
tau mice or C57BL/6 OlaHsd (Harlan) mice and incubated with
15µMpFTAA in DMEMmedium containing 20 ng/ml NGF and
1% fetal bovine serum at 4◦C for 15 h, then fixed in 4% PFA
for 20min at room temperature. Following studies of the time
course and dose-dependence to establish the best conditions for
pFTAA labeling of tau, it was determined that an incubation
of 30min with 3µM pFTAA was sufficient to label filamentous
tau+ve DRG neurons to the same extent as higher concentrations
and longer times. Before labeling, ganglia were permeabilised
by incubating with acetone or PBS with 0.3% triton X-100 as
described for the brain sections. Ganglia were bisected with a
scalpel blade to facilitate antibody penetration. Antibodies were
either added in PBS (if acetone was used) or PBS with 0.3% triton
X-100.
Dissociated DRG neurons were fixed on ice with 95% ethanol
kept at −20◦C, then rehydrated through 70% and 50% alcohol
and water before storage at 4◦C in PBS with 0.1% azide. Ice-
cold methanol (100%) was equally effective at fixation. pFTAA
diluted in PBS was added to fixed neurons or in growth medium
when added to living neurons. Neurons were washed in PBS
before the addition of primary antibodies. Incubation in primary
antibody solution was at 4◦C over night for cultured neurons,
or 2 days at 4◦C for brain sections or whole DRG to facilitate
antibody penetration into the tissue. After washes in PBS,
secondary antibody was applied for 1 h (cultures) or 1 day (brain
sections, whole DRG) in the same buffers used for primary
antibodies. Brain sections or cultures on coverslips weremounted
in FluorSave™ (Calbiochem).
Antibodies
Anti-phospho-tau AT100 (epitope pT212/pS214, MN1060) and
anti-human tau HT7 (epitope 159–163, MN1000) mouse
monoclonal antibodies were from Thermo Scientific and
used at 1:1000 or 1:500 dilution, respectively. Hybridoma
culture supernatant containing MC1 was a kind gift from
Dr. P Davies, Albert Einstein College of Medicine, New
York and used at 1:500-1:1000 dilution. Anti-β-III tubulin
antibody was from Covance (PRB-435P-100) and used at
1:1000 dilution. AlexaFluor R©568/647/350 conjugated secondary
antibodies (Invitrogen) appropriate for the species were used at
1:1000 dilution. pFTAA was excited using the L5 filter (Leica).
No significant fluorescent emission of pFTAA bound to tau was
detected upon excitation at 540/50 nm, the wavelength used to
excite AlexaFluor R©568.
Imaging and Data Analysis
Imaging was performed using a Leica DMI 4000 B microscope
and Leica-LAF software. Images were exported in TIFF
format and figures compiled using Adobe Photoshop CS3.
Quantification of concordance rates between pFTAA+ve
neurons and co-stains was achieved by imaging 30 random fields
at 20x magnification across 3 biological replicates, yielding 133–
224 pFTAA+ve cells. Subsequent analysis used ImageJ (Rasband,
W.S., ImageJ, U. S. National Institutes of Health, Bethesda,
Maryland, USA, http://imagej.nih.gov/ij/, 1997–2014). Sampling
for calculation of the half saturation constant was achieved by
imaging 15 randomly chosen pFTAA+ve cells per concentration.
Relative fluorescence intensity of each pFTAA+ve neuron per
concentration was quantified using the ImageJ Measure tool.
Microscope settings were: filter cube L5, intensity 5, exposure
170ms, gain 1. The half saturation constant and the coefficient of
determination (R2) values were determined using the non-linear
least squares curve-fitting program http://faculty.gvsu.edu/
carlsont/232lab/nonlin2.html. To determine the rate of cell
death, the number of pFTAA+ve cells that became PI positive
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and/or were subsequently lost from the culture, were expressed
as a percent of total pFTAA+ve neurons imaged at t = 0 in
3 biological replicates. Significance of changes were calculated
by one sample t-test. The number of pFTAA-ve neurons was
identified by phase contrast morphology in the same fields as
those used to image pFTAA+ve neurons, and were counted at
onset of the experiment and after 25 days in vitro. Significance of
difference between the percentage of pFTAA+ve and pFTAA-ve
neurons remaining in the dish was determined by a paired t-test.
Results
Wefirst examined whether DRG neurons in P301S tau transgenic
mice—like CNS neurons (Klingstedt et al., 2013)—were labeled
after injection of pFTAA in vivo, and whether pFTAA-labeled
neurons co-label with antibodies that detect insoluble tau
aggregates and fibrils. Figure 1A shows an overview of a
brain section taken from the level of the anterior commissure;
pFTAA labeled numerous neurons in the upper and deeper
layers of the motor cortex, and most of the neurons in the
piriform cortex, but none in the striatum. This labeling occurred
exclusively in P301S tau+ve neurons, detected with the human-
specific tau antibody HT7 (Figures 1B–D), and coincided with
positive immunolabeling with the anti-phospho (pT212/pS214)
tau antibody AT100 (Figures 1B,C), which only recognizes
sarkosyl-insoluble, but not soluble, tau in the CNS of P301S
tau mice (Delobel et al., 2008). Due to comparatively poorer
antibody penetration compared to pFTAA, some structures
that first appeared HT7- or AT100-negative, were found to be
positively stained after increasing the camera exposure time.
Colocalization was also obtained after immunolabeling with the
anti-phospho (pSer202/pThr205) tau antibody AT8, which binds
to filamentous tau but also binds to soluble hyperphosphorylated
tau (Delobel et al., 2008) (data not shown). A subset of neurons
in the DRG were also labeled with pFTAA and, as in the brain,
this labeling coincided with immunolabeling with HT7 or the
MC1 antibody (Figure 1D), which detects a conformational
change in tau that is associated with neurofibrillary tangles in
human AD brains (Weaver et al., 2000) and is only evident
in DRG neurons from P301S tau mice when they are also
AT100+ve (Mellone et al., 2013). In biochemical studies, MC1
was shown to bind with the highest affinity to a compacted
“paper clip” form of misfolded tau when the protein is pseudo-
phosphorylated at the three epitopes recognized by the antibody
PHF-1 [which stains most of the HT7+ve DRG neurons
from P301S tau mice (Mellone et al., 2013)], AT8 and AT100
antibodies (Jeganathan et al., 2012). It should be noted that
only 7–20% of DRG neurons are P301S tau (HT7)+ve in
ganglia from 5-month-old P301S tau mice (Mellone et al.,
2013).
To investigate whether pFTAA also labels specific DRG
neurons in whole ganglia ex vivo, whole DRG were excised from
5-month-old P301S tau mice or C57BL/6S wild type (wt) mice,
labeled with pFTAA, then fixed and immunostained. Figure 2A
shows that pFTAA did not label any DRG neurons in ganglia
from wt mice but did label the same subset of neurons in DRG
from P301S tau mice that were also immunolabeled with HT7.
Because the serine 396/404 phospho epitope recognized by PHF-
1 is implicated in high affinity binding of MC1 to tau fibrils, we
also stained the DRG for PHF-1. Figure 2A (bottom row) shows
that there was extensive co-localization of pFTAA and PHF-1+ve
neurons.
To establish whether pFTAA labeled cultured DRG neurons,
and determine whether this labeling was specific to P301S tau+ve
cells expressing advanced forms of tau pathology, DRG neurons
were cultured from 5-month-old wt C57BL/6S mice, or Alz17
mice, which express the 2N4R isoform of human tau under the
same Thy1.2 promoter encoding a neuron-restricted element as
that used to express P301S tau (Probst et al., 2000; Clavaguera
et al., 2009), and 2- or 5-month-old P301S tau mice. After 2 days,
cultures were fixed, and stained with pFTAA. Figure 2B shows
that no staining of pFTAA was detected in wt DRG neurons,
nor in HT7+ve neurons from Alz17 mice, which do not express
filamentous tau aggregates at this age, nor in HT7+ve neurons
from 2-month-old P301S tau mice, a stage when they express
P301S tau protein but do not form insoluble tau fibrils (Delobel
et al., 2008). By contrast, pFTAA stained 44.1± 0.9% of HT7+ve,
81.0± 11.4% of AT100+ve, and 87.3± 4.3% ofMC1+ve neurons
(mean ± SD, 3 independent cultures) cultured from 5-month-
old P301S tau mice (Figure 2C). The lower percentage of pFTAA
staining of HT7+ve neurons compared to AT100 or MC1+ve
neurons reflects the fact that only ∼40% of HT7+ve neurons
taken from this stage have developed the advanced stages of tau
aggregation that is detected by the AT100 and MC1 antibodies
(Mellone et al., 2013).
To further verify that pFTAA was binding to insoluble
filamentous tau, cultured DRG neurons were imaged before
and after formic acid treatment, which solubilizes filamentous
tau in brain sections from Alzheimer’s disease patients (Bing
et al., 2006) and in brain sections from P301S tau mice (Velasco
et al., 2008). DRG neurons were fixed, stained with pFTAA,
and immunolabeled with MC1 and HT7 antibodies. Cells were
imaged, then treated with 90% formic acid for 15min after
which the same cells were re-stained with pFTAA, re-probed
with the indicated antibodies, and re-imaged. Figure 3 shows
that no pFTAA or MC1 staining was detected after incubation
with formic acid, whereas HT7 immunostaining was still strongly
visible. Hence, the pFTAAbinding site is present only in insoluble
tau with a pathological conformation.
The high signal to noise ratio of the pFTAA staining pattern
prompted us to run a dose response curve to determine
the relative affinity of pFTAA to P301S tau in the neurons.
For this purpose, DRG neurons from 5-month-old P301S
tau mice were cultured for 2 days, fixed, and stained with
varying concentrations (0.0015–15µM) of pFTAA. Figure 4A
shows representative images of neurons stained with the
different concentrations of pFTAA, while the average relative
fluorescence intensity measurements from 15 random neurons
per concentration are plotted in Figure 4B. To determine the
half saturation constant (EC50), the data were fitted to an
equation that assumes a single, saturable binding site (Flmaxx
[pFTAA])/(EC50 + [pFTAA]) by non-linear curve fitting, from
which an EC50 value of 0.142µM was calculated with a
correlation coefficient of 0.983 over the entire fit. Such a high
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FIGURE 1 | Labeling of tau inclusions in the brain and DRG of
5-month-old P301S transgenic mouse by pFTAA. A P301S tau
transgenic mouse injected with 150 nmole pFTAA via the tail vein was
perfused after 48 h. (A) A composite image of a 30µm coronal brain
section at the level of the anterior commissure (5x objective) showing the
general staining pattern of pFTAA+ve neurons; staining is found almost
exclusively in the cortex. MC, motor M1 cortex, PC, piriform cortex. (B)
motor M1 cortex and (C) piriform cortex stained with pFTAA (green) and
immunolabeled with anti-human tau antibody HT7, or anti-fibrillar
phospho-tau-specific antibody AT100 (red). (D) whole mount of a DRG
stained with pFTAA in vivo (green) and immunolabeled with anti-human
tau antibody HT7, or the conformational anti-tau antibody MC1 (red).
Note that due to poorer penetration of the antibodies compared to
pFTAA, some pFTAA+ve neurons that appear HT7-ve at the exposure
shown are co-stained by the antibodies upon increased exposure. Scale
bar, 1mm (A) 100µm (B,C), 250µm (D).
affinity is unique to pFTAA as it was impossible to resolve
any specific binding using FSB or thioflavin T/S at similar
concentrations.
To examine whether live DRG neurons expressing insoluble
tau would be detected with pFTAA, and whether it was the
fixation that induced a conformation that allowed the binding
of pFTAA to P301S tau, 2-day cultures of DRG neurons from
5-month-old mice were incubated with 3µM pFTAA (rather
than the higher concentration used in fixed cultures in order to
minimize background fluorescence) for 30min and then fixed,
or fixed first and then stained with the same pFTAA solution.
Figure 5 shows that pFTAA stained similar profiles of HT7+ve
neurons in live cultures before fixation as those that were fixed
prior to staining. Hence, the conformation of tau detected by
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FIGURE 2 | pFTAA selectively labels fibrillar tau in DRG neurons
in intact DRG ex vivo and cultured dissociated DRG neurons
from 5-month-old P301S tau transgenic mice. (A) Intact DRG
from 5-month-old C57BL/6 OlaHsd (wt, top row) or P301S tau
mice (middle row) were incubated with 15µM pFTAA at 4◦C for
15 h, then fixed in 95% ethanol, rehydrated, and immunolabeling
(red) with the HT7 antibody. Bottom row shows immunolabeling
with the PHF-1 antibody (which recognizes phospho-serines396/404).
Magnification box identifies pFTAA+ve threads visible in the axons
of whole ganglia (arrows). Non-specific signal in wt intact ganglia is
a-cellular debris carried over because of re-use of the dye. (B)
DRG neurons were cultured from 5-month-old C57BL/6 OlaHsd wild
type mice, or Alz17 mice transgenic for the longest isoform of
human tau (2N4R), or 2-month-old P301S tau mice for 2 days.
After ethanol fixation, cultures were labeled with pFTAA and
immunolabeled with HT7. Note absence of pFTAA staining but
presence of human tau in the neurons from Alz17 and 2-month-old
P301S tau mice. (C) Dissociated DRG neurons from 5-month-old
P301S tau mice were labeled after ethanol fixation by pFTAA
(green), as well as for AT100 or MC1 (red). Images are
representative of 133–224 pFTAA+ve cells across 3 biological
replicates. Scale bar, 200µm in (A) 20µm in (B,C).
pFTAA is preformed in the neurons and is not induced after – or
by – fixation, as also demonstrated after delivering pFTAA in vivo
or in ganglia stained by pFTAA before fixation.
Prior to the use of pFTAA, neurons had to be fixed and
stained with antibodies to detect those neurons containing
advanced forms of aggregated tau. This meant that the same
field of live neurons that had been studied, for example, to
follow mitochondrial transport, had to be retraced after fixation
and antibody staining (Mellone et al., 2013). Given the positive
detection of neurons containing fibrillar tau using pFTAA, we
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FIGURE 3 | Formic acid treatment solubilizes fibrillar tau, but not
souble tau, and eliminates the binding of pFTAA. DRG neurons
cultured from 5-month-old P301S tau mice for 2 days were fixed with
95% ethanol. Top row shows pFTAA+ve neurons immunolabeled with
HT7 (red) and MC1 (blue) antibodies. Bottom row shows the same set of
neurons re-stained with pFTAA and antibodies after a 15min treatment
with 90% formic acid. Note that formic acid treatment prevented the
re-binding of pFTAA and the MC1 antibody whereas the interaction with
HT7, which binds to soluble and insoluble tau, was restored. Scale bar,
50µm.
FIGURE 4 | A dose response of pFTAA demonstrates a single,
homogeneous binding site to neurons expressing filamentous tau.
pFTAA was added at the concentrations indicated to ethanol-fixed DRG
neurons cultured from 5-month-old P301S tau mice for 2 days. (A)
Representative images of pFTAA binding intensities at the concentrations
indicated. (B) Quantification of signal intensity. To determine the relationship
between the concentration of pFTAA and fluorescence intensity, the
fluorescence intensity values from 15 neurons per dose were averaged
(circles) and the results were submitted to a least square curve fitting analysis
according to an equation that predicts a single, saturable binding site (line)
from which a half saturation constant of 0.142µM (R2 = 0.983) was derived.
Error bars indicate sem values. Scale bar, 100µm.
asked whether we could visualize the progression of processes
that occur in these neurons over longer periods of time. One such
process of interest is the mechanism of cell death. As mentioned
above, there is an ongoing debate as to tau+ve neurofibrillary
tangles induce cell death or whether these protein aggregates
are benign or even protective. We reported the loss of AT8
and AT100+ve neurons in long-term cultures of DRG neurons
from P301S tau mice, but could not establish whether this was
due to intrinsic properties or to do with post-fixation handling,
as neurons that die tend to detach and disappear. To examine
whether P301S tau+ve neurons with fibrillar tau were dying at a
measurable rate in long-term cultures, we labeled neurons with
pFTAA and used PI to track cell death in the labeled population
over 25 days. Figure 6 shows that identified pFTAA+ve neurons
lost plasma membrane integrity and/or disappeared from the
cultures over this period while the majority of the unlabeled cells
remained PI-negative, except for the occasional appearance of
a PI+ve cell, as shown in the image from t = 2 days. The
number of surviving cells was significantly different (p < 0.0144)
from day 10 in vitro (3 days from the time pFTAA was added)
onwards. It is unlikely that pFTAA was toxic, as the percentage
of surviving pFTAA-ve cells identified by phase contrast at day
25 was significantly higher than that of pFTAA+ve cells (p =
0.0318, paired t-test).
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FIGURE 5 | Labeling of insoluble tau is not an artifact of fixation.
DRG neurons cultured from 5-month-old P301S tau mice for 2 days were
either incubated with 3µM pFTAA for 30min at room temperature before
fixation in 95% ethanol, or fixed before labeling with pFTAA using the
same solution and conditions. Cultures were immunolabeled with the HT7
antibody (red). Loading of pFTAA into either live or fixed dissociated DRG
neurons produced equivalent signal and co-localization with HT7. Note
that some HT7+ve neurons are not labeled with pFTAA because HT7
neurons with insoluble tau only represent about 44% of all the HT7+ve
neurons. Scale bar, 100µm.
Discussion
Misfolded and hyperphosphorylated tau is now known to be at
the fulcrum of many neurodegenerative diseases and it is thus
of major interest to understand how it exerts its toxic effects.
One of the limitations of current studies aimed at understanding
the actions of NFTs (and other abnormally misfolded proteins)
in neurodegenerative diseases is the lack of dyes that detect
aggregates and fibrils in living neurons. There are many dyes
that stain protein preparations of fibrillar tau but few that have
been useful for detecting fibrillar tau in living neurons in animal
models (Velasco et al., 2008) or in culture (Bandyopadhyay et al.,
2007; Lira-De Leon et al., 2013) without toxicity. Kuchibhotla
et al. (2014) reported that Methoxy X-04 delivered via the eye
vein rapidly detects NFTs in the visual cortex of P301L tau
transgenic mice but noted the dye’s near-full depletion from the
brain within 24 h. Because of its rapid reversibility, they could
not corroborate that the dye stained exclusively insoluble NFTs
by using antibodies, as they did using the well-established dye
Thioflavin S in fixed tissue. We developed the DRG neuron
culture system because it can be established from adult mice, the
neurons develop pathological forms of tau at the same rate as
those that develop in CNS neurons, and some of these properties
develop and are maintained during long-term cultures (Mellone
et al., 2013).
The present work shows that pFTAA is a non-toxic, high
affinity, rapid-acting, and highly specific dye for detection of
fibrillar (but not soluble) tau in living neurons in vivo, ex vivo
and in dissociated cultures of neurons. That the binding of
pFTAA is specific to fibrillar tau is shown by the high degree
of overlap between pFTAA-labeled neurons and neurons that
express the AT100 and MC1 epitopes. Moreover, solubilization
of fibrillar tau with formic acid disabled pFTAA binding and
MC1 immunolabeling whilst soluble P301S tau detected by
HT7 immunolabeling was still abundant in the neurons. pFTAA
stained not only the cell bodies of neurons but also the axons,
exemplified in the images of intact DRG ganglia (Figure 2A) and
in the cultures (Figure 2B), coinciding with immunolabeling for
AT100 or MC1.
To our knowledge the affinity of dyes that bind to fibrillar
tau in primary neurons has not been reported previously. In
neuroblastoma SH-SY5Y cells, uptake and cell viability of the
most commonly used pro-aggregating anionic dyes Congo red
(CR), Thioflavin S (ThS) and Thiazine Red (TR) were measured
after 7 days of treatment (Lira-De Leon et al., 2013). Congo red
stained the highest number of cells (55% at 5µM) and no toxicity
was reported. However, EC50 values for ThS and TRwere around
75 and 45µM, respectively, but viability was commensurately
reduced even at the lowest concentrations (5µM). Moreover,
these compounds induced aggresome-like structures rather than
reporting on their presence, whereas pFTAA is a reporter without
evident inducing or dispersing activity. Bandyopadhyay and
colleagues (Bandyopadhyay et al., 2007) reported that 10µM
Congo red induced NP40-resistant aggregates in cell pellets from
HEK-293T cells expressing human tau, but no uptake of ThS
or TR was detected. However, CR also induced considerable
toxicity. Due to its high affinity to fibrillar tau, it is tempting to
speculate that higher concentrations pFTAA might be used to
dissociate NFTs or perturb NFT formation. However, Wegenast-
Braun and colleagues showed that repeated weekly intravenous
injection of pFTAA at concentrations similar to those used in our
study for up to 6 months produced no inhibitory effect on A-beta
aggregate formation (Wegenast-Braun et al., 2012). Furthermore,
over 25 days in vitro we did not observe any instances of living
pFTAA+ve neurons that subsequently became pFTAA-ve despite
having added a concentration of pFTAA that is 20-fold higher
than the half saturation constant of the dye. More work using
even higher concentrations will have to be conducted to assess
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FIGURE 6 | Slow death of defined DRG neurons expressing fibrillar
tau can be followed continuously after labeling with pFTAA. DRG
neurons were cultured from 5-month-old P301S tau mice for 7 days
before labeling with 3µM pFTAA, (t = time in days after addition of
pFTAA). Medium was replaced with PI-containing medium without pFTAA
every 3 days. (A) Images of the same set of neurons at 0, 2, and 7 days
after addition of pFTAA showing appearance of PI+ve neurons and their
subsequent disappearance from the cultures. (B) The loss of pFTAA+ve
neurons as a percentage of total neurons originally labeled is 45% after
25 days in vitro. The loss of pFTAA+ve neurons becomes significant at
10 days in vitro (p = 0.0144) and continues to increase until 25 days
in vitro (p = 0.0017). Black square denotes percentage survival of
pFTAA-ve neurons in the same culture after 25 days (mean ± sem from
the three biological replicates, p = 0.0318, paired t-test). Scale bar, 50µm.
whether pFTAA-bound fibrillar tau remains stable over longer
times.
We measured the affinity of pFTAA to fixed DRG neurons
from P301S tau mice, finding a half saturation constant of
0.142µM with a remarkably high correlation coefficient of 0.983
after fitting the data to a binding curve that assumes a single
saturable binding site. Even though fibrillar tau may contain
more than one binding site per molecule, and several binding
sites per cell, it appears that there is no interaction between these
individual binding sites (otherwise the curve would show positive
or negative cooperativity). It will be interesting to compare this
value to that of binding of pFTAA to pure fibrils of tau to
determine the relationship between the macroscopic binding to
cells and the microscopic binding parameters of the individual
fibrils. Unfortunately at present it is not possible to form fibrils
of pure tau without resort to fibril-initiating compounds such as
polyanions or seeds of fibrillar tau. Hence this data is the first of
its kind to probe binding parameters of dyes that are specific to
preformed fibrillar tau in neurons.
Along with the relatively high affinity of pFTAA to the fibrils,
we found that pFTAA is rapid acting: the shortest time between
adding 3µM pFTAA to the neurons and inspecting them under
the microscope was 10min and already by this time, the intensity
of labeling the neurons appeared to be maximal compared to the
values obtained 30min later. Unlike Methoxy X-04 (Kuchibhotla
et al., 2014) pFTAA labeling in our mice remained extensive
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after 48 h and is still detectable 6 months later in fixed brain
slices despite extensive washing. Having found that pFTAA labels
fibrillar tau in living neurons, we utilized the dye to follow a
defined set of neurons over 25 days to examine whether they
undergo cell death. We used PI to label dying cells as it is not
toxic to living neurons, but because necrotic cells tend to detach
from the substrate a short time after they die, we also recorded
loss of pFTAA+ve neurons. We found that the rate of cell death
appeared to follow two phases; a more rapid phase that lasted
over 14 days, and a slower phase that lasted until the end of the
study. The reason for this biphasic response is not clear. Since
the neurons were cultured for 7 days prior to onset of labeling,
it is unlikely that the faster-dying neurons were damaged due to
culture preparation. However, unpublished work from our lab
indicates that there is high variability in the oxidative status of
P301S tau-expressing neurons, which may sensitize a stochastic
subset of neurons to death. Nevertheless, it is clear that a sizeable
population of the neurons containing fibrillar tau can survive
25 days in culture. Previously, Wegenast-Braun et al. (2012)
injected pFTAA to label β-amyloid in APP23 and tau in P301S
mice and found no discernable toxicity (Wegenast-Braun et al.,
2012). Data presented here corroborates this observation, since
several pFTAA+ve neurons survived for 25 day. Additionally,
significantly more pFTAA-ve neurons remained viable after 25
days, indicating that the cell death we observed was not due
to toxicity but was associated with fibrillar tau. Elucidating the
properties of the relatively resistant neurons, which can now be
distinguished by using pFTAA, may provide a clue to the factors
that are required to resist the possible toxicity of fibrillar tau.
There are some limitations to the use of pFTAA that are
worth noting. One proviso was that some neurons appeared to
be stained without apparent presence of P301S tau. In some
cases, on closer inspection using higher intensity illumination,
there was a small remnant of HT7 labeling though the pFTAA
still appeared to label a larger part of the neuronal cell body.
However, pFTAA also labeled a few a priori dead neurons in
the culture but these were readily distinguishable under light
microscopy as phase dark and grainy. We did not remove the
stained dead cells from consideration when we calculated the
percentage of pFTAA+ve neurons that were AT100 or MC1+ve,
thus accounting for the small percentage of neurons that were
recorded as pFTAA+ve but were antibody-negative. Another
aspect worth noting is the longevity of pFTAA binding. Although
it has been retained without notable fade over several months
in the brain sections and ganglia after in vivo labeling, in the
living cultures, the intensity of pFTAA staining waned over time,
though it was still discernable 25 days later. Although we did not
replenish the pFTAA in these experiments, adding fresh pFTAA
to another set of neurons renewed the staining to the same
intensity as that which was recorded after first application. The
fade was unlikely to be due to photobleaching, since a continuous
60-min exposure of fixed pFTAA+ve neurons under continuous
illumination at the same intensity we use to image pFTAA
in the neurons produced minimal loss of fluorescence (see
graph here: https://www.dropbox.com/s/1xwyq5bbgoebvmm/
pFTAA%20photobleaching.tiff?dl=0). The cumulative intensity
x time of exposure in this experiment is 300-fold higher
than the intensity the neurons would have been exposed to
during the experiment. A more careful quantitative analysis
of pFTAA binding intensity together with periodic addition of
another vital dye that differentiates neurons with newly-formed
fibrillar tau from those stained initially may help inform on
the mechanisms of formation and turnover of fibrils in living
neurons.
Identifying living neurons containing fibrillar tau with pFTAA
opens up many research opportunities. Of utmost interest is the
understanding of mechanisms by which neurons with advanced
forms of tau pathology die. Although PI labels cells whose plasma
membrane is ruptured, the neurons may have followed one of
several cell death pathways that culminate in necrosis (Green and
Victor, 2012). We can now study these processes by intervening
in key steps of each putative death pathway in these identified
neurons without having to sample all the neurons and identify
those affected after fixation. The strong binding of pFTAA to
fibrillar tau over long periods of time coupled to evidence that the
dye will dissociate when the fibrils are solubilized will allow us
to monitor disaggregation when testing anti-aggregation drugs,
and follow at the same time other cellular processes that may
participate in the disaggregation process. Likewise, it will be
possible to monitor the events leading up to fibrillization as
detected by pFTAA and determine the intracellular processes
that contribute to the fibrillization process. Finally, we can
now purify neurons with fibrillar tau from, for example, the
cortex of P301S tau mice, allowing us to develop a biochemical
approach to elucidate the mechanisms underlying dysfunction
and death of neurons with fibrillar tau. Ultimately, elucidating
the events that lead to fibrillar tau formation and neuronal death
in our models may have direct relevance to other models of
human neurodegenerative diseases, and to the human system in
particular.
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